new glp-1 agonists Mechanisms by which may exert beneficial effects on the GLP-1 Receptor Agonists: The New

Clinical trials for the treatment of diabetes and obesity have included GLP-1 analogs, which share 97 % sequence identity with human GLP-1

Not everyone who experiences a Chronic Illness will have MCAS, but it is estimated that 50% of people with Chronic Illness have MCAS or histamine intolerance and therefore it can be common territory for those with chronic fatigue, post-viral fatigue, long covid or other energy limiting illness

Saltiel, A

In the SCALE Sleep Apnea trial, liraglutide led to a SBP reduction of 4.1 mm Hg, paralleling improvements in the apnea-hypopnea index, among patients with obesity and moderate-to-severe OSA

doi: 10.1523/JNEUROSCI.6326-11.2012 34 MerchenthalerILaneMShughrueP

Endocrinology 2010;151(4):14731486